DM 199

Drug Profile

DM 199

Alternative Names: DM-199; DM-99; Recombinant human tissue kallikrein-1 - DiaMedica Therapeutics; rhKLK-1 - DiaMedica

Latest Information Update: 04 Oct 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator DiaMedica
  • Developer DiaMedica; DiaMedica Therapeutics
  • Class Antidementias; Antihyperglycaemics; Antirheumatics; Insulin sensitisers; Nootropics; Recombinant proteins
  • Mechanism of Action Tissue kallikrein-replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Stroke; Type 2 diabetes mellitus
  • Phase I Diabetic nephropathies
  • Research Acute kidney injury
  • No development reported Alzheimer's disease; Nephritis; Rheumatoid arthritis; Type 1 diabetes mellitus

Most Recent Events

  • 27 Sep 2018 DM 199 licensed to Ahon Pharmaceutical in China, Taiwan, Hong Kong and Macau
  • 05 Sep 2018 DM 199 is still in phase I trials for Diabetic nephropathy in USA
  • 05 Sep 2018 DiaMedica Therapeutics plans a clinical trial for Chronic kidney disease (Diabetic nephropathy)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top